Because I realise the importance of cash & debt levels to keep a great company a going concern .... at the Sydney preso i asked the question, which was essentially, how do we pay the monthly bills moving forward. Mohammad advised monthly spend continues to be pegged at 'approx $250K'.
IMO not huge but still a sizeable spend for a company with out sales revenue. Yes we have cash from a Share Placement Plan and the sale of non core assets but that is finite and yes we hopefully have cash from Govt grants. And no we dont want a mother diluting CR.
I see Archer (yes there will be a pun here) as pulling back on the bow. The more we pull back (RnD/carefully choosing directions etc) the more force with which the arrow flys forward. The longer we pull back also gives us more time to really finesse our aim. Its just about picking that optimal launch point....the point where we let go of the bows string.
I'm in for the LT and have been happily accumulating along the way (yesterday was even an opportunity taken and at the highest i have ever paid) ...so I'm happy for all this to happen That said I would also love to see some cash come in from sales revenue (its akin to someone holding the bow string back for us, retaining the potential energy forward, but taking the pressure off the Archer
It dawned on me when reading the Graphene Biosensor Preso update - I read this and realised we don't necessarily have to build something (an often costly and timely capital outlay) we can licence the IP. Essentially we would be selling, at a hefty price, the 'smarts' and invested work (ie. the ideas) of people onboard like Dr Mohammad Choucair (PHD) and Dr Martin Fuechsle (PHD) through licensing agreements. If this strategically happens I'm a happy camper.
Taken from the Presentation update:"Archer intends to commercialise the biosensing technology by seeking to establish commercial partnerships, including licencing agreements, with highly resourced organisations including biotechnology companies."
(20min delay)